Delivery Order SPE2DB20D3303-SPE2DB25FA2UF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- The Defense Logistics Agency awarded a $1,725.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $45,421.87 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s. This contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was competitively procured and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Creon is a pancreatic enzyme replacement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with a contract value of $9,718.75. The order was competitively awarded without set-aside designation and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates under a firm...
- The Defense Logistics Agency awarded a delivery order valued at $2,478.80 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules. This competitive, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The firm fixed-price delivery order represents a routine pharmaceutical procurement to support federal medical supply needs, likely for military...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order valued at $42,783.63 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of 36,000 units of Creon DR 100s capsules. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,212.12 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 24,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This contract, which is non-competitive and carries a firm fixed-price structure, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The order is scheduled for completion by August 14, 2025, and will be fulfilled from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,117.97 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon DR 100s. This competitively awarded contract, which carries no set-aside designation, was executed on August 13, 2025, with an ultimate completion date of August 14, 2025. The firm fixed price delivery order will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2UFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,299.69 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon in 100-count bottles. This competitive, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that enables the contractor to supply comprehensive pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of federal contract awards with DLA and other government healthcare systems, specializing in brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/20/25 |